PE-22-28
INSUFFICIENT EVIDENCEAlso known as: Spadin analogue
Investigational — not approved for human use
Educational Overview
A spadin-derived peptide studied in animal models for effects on TREK-1 channel activity.
Research Mechanism
Studied as a TREK-1 potassium channel blocker in preclinical neurological research.
Areas of Study
- TREK-1 channel research (preclinical)
Safety Considerations
Human safety is not established. Evidence is limited to animal models. Research material only.
Frequently Asked Questions
Is this approved for human use?
No. This material is supplied for laboratory research use only by qualified businesses and institutions. It is not a medicine and is not for human or veterinary consumption.
How do I get pricing?
Request a quote and our team will respond with current pricing and available sizes for your account.
Do you provide purity documentation?
Certificates of analysis are available to approved accounts. Contact our team for batch-specific documentation.
References
References pending editorial review
We publish citations only after a qualified reviewer has verified them against the primary literature. We do not list references we have not checked. (1 queued.)
Last reviewed: 2026-07-23 · Status: in_review · References verified by editorial review before publication.
Disclaimer: Educational only. Not medical advice, diagnosis, or treatment. For research and educational purposes. Consult a licensed medical professional.